Stock SGMO SANGAMO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Sangamo Therapeutics, Inc.

Equities

SGMO

US8006771062

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-16 pm EDT 		5-day change 1st Jan Change
0.542 USD -2.36% Intraday chart for Sangamo Therapeutics, Inc. -3.63% -0.24%
Mar. 22 Sangamo Therapeutics Prices $24 Million Registered Direct Offering MT
Mar. 14 Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
AQ
Sangamo Therapeutics Prices $24 Million Registered Direct Offering
MT
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
BU
Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says
MT
Transcript : Sangamo Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024
Sangamo: Q4 Earnings Snapshot
AQ
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
BU
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs
BU
Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023
CI
Sangamo Therapeutics Announces Data from Novel Proprietary Neurotropic Aav Capsid Demonstrating Industry-Leading Blood-Brain Barrier Penetration and Brain Transduction in Nhps
CI
Sangamo Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Sangamo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
BU
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
BU
Sangamo Therapeutics Says Early Phase 1/2 Data Shows 'Durable' Safety, Efficacy of Fabry Disease Drug Candidate
MT
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
BU
Sangamo Therapeutics, Inc. Announces Updated Preliminary Data from the Phase 1/2 STAAR Clinical Study Evaluating Isaralgagene Civaparvovec, or ST-920
CI
Vaxcyte Names Chief People Officer
MT
Sangamo Therapeutics, Inc.(NasdaqGS:SGMO) dropped from NASDAQ Biotechnology Index
CI
Sangamo Therapeutics, Inc Announces Pivotal Readout in the Middle of 2024 for the Phase 3 Affine Trial
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SGMO Stock
  4. News Sangamo Therapeutics, Inc.